Sugi Predict

Sugi Predict / Compounds / SCHEMBL15417954

SCHEMBL15417954

SCHEMBL15417954

COCCCOc1cc(Br)ccc1C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ HSP90AA1 P07900 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ HPGD P15428 3/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ NR4A2 P43354 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20098234 0.93 HPGD (0.46) KDM4EKMT2ASMN1; SMN2NPC1LMNA
SCHEMBL15198836 0.90 TDP1 (0.49) KDM4EKMT2ASMN1; SMN2NPC1LMNA
SCHEMBL27146483 0.89 ALDH1A1 (0.45) KDM4EKMT2ASMN1; SMN2NPC1LMNA
SCHEMBL17959008 0.87 TDP1 (0.44) KDM4EKMT2ASMN1; SMN2RAB9AHSP90AA1
SCHEMBL89047 0.87 PTGDR2 (0.49) KDM4EKMT2ASMN1; SMN2NPC1LMNA
SCHEMBL20562059 0.87 SLC6A3 (0.50) KDM4EKMT2ASMN1; SMN2LMNAHSP90AA1
SCHEMBL15417960 0.87 KDM4E (0.51) KDM4EKMT2ASMN1; SMN2NPC1LMNA
SCHEMBL20471958 0.86 TDP1 (0.43) KDM4EKMT2ASMN1; SMN2LMNARAB9A
SCHEMBL24502272 0.85 TDP1 (0.45) KDM4EKMT2AHSP90AA1MAPTHTT
SCHEMBL20563031 0.85 TDP1 (0.45) KDM4EKMT2ASMN1; SMN2HSP90AA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3694856-B1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-10-25 — — EP disclosed
EP-3694856-B1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-10-25 — — EP disclosed
CN-110066278-B Fused tricyclic compound and application thereof in medicines 广东东阳光药业有限公司 2021-06-08 — — CN disclosed
US-10966970-B2 Fused tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-06 — — US disclosed
US-10966970-B2 Fused tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-06 — — US disclosed
EP-3694856-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE Sunshine Lake Pharma Co., Ltd. (CN) 2020-08-19 — — EP disclosed
US-20200113879-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-04-16 — — US disclosed
WO-2019100735-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-05-31 — — WO disclosed
WO-2019100735-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-05-31 — — WO disclosed
US-10155731-B2 Nitrogen-containing saturated heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-12-18 — — US disclosed
US-9278944-B2 Nitrogen-containing saturated heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-03-08 — — US disclosed
EP-2933248-A1 NOVEL RENIN INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2015-10-21 — — EP disclosed
EP-2933248-A1 NOVEL RENIN INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2015-10-21 — — EP disclosed
US-20150232459-A1 NOVEL RENIN INHIBITOR SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-08-20 — — US disclosed
US-20150232459-A1 NOVEL RENIN INHIBITOR SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-08-20 — — US disclosed
EP-2687518-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2014-01-22 — — EP disclosed
EP-2687518-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2014-01-22 — — EP disclosed
US-20140011807-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2014-01-09 — — US disclosed
US-20140011807-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2014-01-09 — — US disclosed
WO-2012124775-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 (JP) 2012-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011807-A1 NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND REN, AGTR1, AGTR2 KDM4E 1787/4885KMT2A 721/4885SMN1; SMN2 3926/4885
US-10155731-B2 Nitrogen-containing saturated heterocyclic compound REN, AGTR1, AGTR2 KDM4E 1787/4885KMT2A 721/4885SMN1; SMN2 3926/4885
US-20150232459-A1 NOVEL RENIN INHIBITOR REN, AGTR1, ACE KDM4E 1425/4885KMT2A 1998/4885SMN1; SMN2 4534/4885
US-10966970-B2 Fused tricyclic compounds and uses thereof in medicine SLC10A1, CYP11B2, CYP11B1 KDM4E 4403/4885KMT2A 3954/4885SMN1; SMN2 1949/4885
US-20200113879-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SLC10A1, CYP11B2, CYP11B1 KDM4E 4403/4885KMT2A 3954/4885SMN1; SMN2 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.